During PCE's recent Pulmonary Bootcamp, attendees had the chance to ask our expert faculty a variety of questions related to the topic of connective tissue disease in pulmonary arterial hypertension (CTD-PAH). Here, Kristin B. Highland, MD, MSCR, director of the Rheumatic Lung Disease Program at Cleveland Clinic, and Martha Kingman, FNP-C, DNP, advanced practice provider in the Pulmonary Hypertension Clinic at University of Texas Southwestern Medical School in Dallas, provide answers to the questions addressed during the live presentation. We hope you will find their responses relevant to your practice.
In Partnership With the Association of Pulmonary Advanced Practice Providers
This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Dr Highland: contracted research: Gossamer Bio, Reata, Viela Bio; contracted research/consulting fees: Acceleron; contracted research/consulting fees/fees for non-CME/CE services: Boehringer Ingelheim, United Therapeutics; contracted research/fees for non-CME/CE services: Bayer.
Dr Kingman: consulting fees: Actelion/Johnson & Johnson, Bayer, United Therapeutics.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103121PBC-Q2